Eli Lilly’s investigational GLP-1 receptor agonist orforglipron demonstrated superior blood sugar and weight loss outcomes compared to Novo Nordisk’s oral Rybelsus in a Phase 3 trial. The highest dose of orforglipron reduced A1C by 1.9 points versus 1.5 points for Rybelsus, while inducing 8.2% and 5.3% weight loss respectively. Additionally, new obesity data presented at EASD and regulatory filings seeking pediatric approval for Mounjaro emphasize Lilly’s commitment to expanding its metabolic disease portfolio amid fierce competition.